|Bid||2.8000 x 4000|
|Ask||2.8500 x 2900|
|Day's range||2.5600 - 2.8100|
|52-week range||2.5600 - 112.8700|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||26.75|
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis i
Allakos Inc. (ALLK) closed at $3.86 in the latest trading session, marking a -1.03% move from the prior day.
In the latest trading session, Allakos Inc. (ALLK) closed at $5.46, marking a +0.18% move from the previous day.